Evidence map›Paper›PMID 25894543›Full record

ArticlePloS one2015

Toward a Broader View of Ube3a in a Mouse Model of Angelman Syndrome: Expression in Brain, Spinal Cord, Sciatic Nerve and Glial Cells.

Mark D Grier, Robert P Carson, Andre Hollis Lagrange

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Article
  3. Unraveling the Roles of UBE3A in Neurodevelopment and Neurodegeneration.International journal of molecular sciences · 2025
    Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Mark D GrierDepartment of Neurology, Vanderbilt University Medical Center, Nashville, TN 37232-8552, United States of America.
Robert P CarsonDepartment of Neurology, Vanderbilt University Medical Center, Nashville, TN 37232-8552, United States of America; Department of Pediatrics, Vanderbilt University Medical Center, Nashville TN 37232-8552, United States of America.
Andre Hollis LagrangeDepartment of Neurology, Vanderbilt University Medical Center, Nashville, TN 37232-8552, United States of America; Department of Neurology, Tennessee Valley Veterans Administration, Nashville, TN 37212, United States of America.
Vanderbilt University Medical Center · USVA Tennessee Valley Healthcare System · US

Funding

mTOR modulation of myelinationK08NS083710 · NINDS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CARSON, ROBERT P · 2013 to 2017
$897k
The Role of TSC Genes During Brain DevelopmentK08NS050484 · NINDS · VANDERBILT UNIVERSITY · PI ESS, KEVIN C · 2007 to 2011
$828k
BLRD VA I01 BX001189NINDS NIH HHS 5K08NS050484NINDS NIH HHS K08 NS050484NINDS NIH HHS K08 NS083710
6 · The paper itself

Abstract

Angelman Syndrome (AS) is a devastating neurodevelopmental disorder characterized by developmental delay, speech impairment, movement disorder, sleep disorders and refractory epilepsy. AS is caused by loss of the Ube3a protein encoded for by the imprinted Ube3a gene. Ube3a is expressed nearly exclusively from the maternal chromosome in mature neurons. While imprinting in neurons of the brain has been well described, the imprinting and expression of Ube3a in other neural tissues remains relatively unexplored. Moreover, given the overwhelming deficits in brain function in AS patients, the possibility of disrupted Ube3a expression in the infratentorial nervous system and its consequent disability have been largely ignored. We evaluated the imprinting status of Ube3a in the spinal cord and sciatic nerve and show that it is also imprinted in these neural tissues. Furthermore, a growing body of clinical and radiological evidence has suggested that myelin dysfunction may contribute to morbidity in many neurodevelopmental syndromes. However, findings regarding Ube3a expression in non-neuronal cells of the brain have varied. Utilizing enriched primary cultures of oligodendrocytes and astrocytes, we show that Ube3a is expressed, but not imprinted in these cell types. Unlike many other neurodevelopmental disorders, AS symptoms do not become apparent until roughly 6 to 12 months of age. To determine the temporal expression pattern and silencing, we analyzed Ube3a expression in AS mice at several time points. We confirm relaxed imprinting of Ube3a in neurons of the postnatal developing cortex, but not in structures in which neurogenesis and migration are more complete. This furthers the hypothesis that the apparently normal window of development in AS patients is supported by an incompletely silenced paternal allele in developing neurons, resulting in a relative preservation of Ube3a expression during this crucial epoch of early development.

Indexed as

AllelesAngelman SyndromeAnimalsAstrocytesBrainCell ExtractsCells, CulturedDisease Models, AnimalFemaleGene SilencingGenomic ImprintingHumansMaleMiceMice, Inbred C57BLNeurogliaCell ExtractsUbe3a protein, mouseUbiquitin-Protein Ligases

Identifiers

PMID25894543
PMCPMC4403805
OpenAlexW2064303101

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.